Formulation and Evaluation of Ritonavir Floating Tablets.

Krishnamurthy A. Kamnapurkar¹, Manmat B. Rumane,¹, Shrishail M. Ghurghure,¹ Sagar S. Sontakke,¹ Imran N. Mujewar.
1. P.G. Department of pharmaceutics, D.S.T.S. Mandal’s college of pharmacy, Solapur-413004 Maharashtra India

ABSTRACT

The aim of present research work was to formulate gastro retentive floating tablets containing Ritonavir. The floating tablets of Ritonavir was formulated by direct compression technique using natural, semi-synthetic and synthetic polymers such as gellan gum, HPMC K4M, and carbopol 971p. Sodium bicarbonate was used as gas generating agent. FTIR studies revealed that there is no interaction between the drug and the polymers used in the formulation. Prepared Ritonavir tablets were evaluated by various quality parameters including weight variation, hardness, friability, drug content, tablet density, floating test, swelling index, in-vitro drug release and showed satisfactory results. Formulations F2, F5, F6 showed satisfactory drug release of 90.3%, 94.3%, and 97.7% respectively. The optimized batch F6 shows good results and extended drug release.

Keywords: Ritonavir, Floating tablet, gellan gum, carbopol 971p, HPMC K 4M.

*Corresponding Author Email: manmathrumane2@rediffmail.com
Received 01 February 2018, Accepted 23 February 2019

Please cite this article as: Rumane MB et al., Formulation and Evaluation of Ritonavir Floating Tablets., American Journal of PharmTech Research 2019.
INTRODUCTION

Gastroretentive dosage forms (GRDFs) are designed to be retained in the stomach for a prolonged time and release their active ingredients and thereby enable sustained and prolonged input of the drug to the upper part of the gastrointestinal (GI) tract.\(^1\) The idea is to prolong the residence time of the drug delivery in the stomach known as gastric residence time (GRT).\(^2\) These are low density systems that have sufficient buoyancy to flow over the gastric contents and are buoyant in the stomach without affecting the gastric emptying rate for a prolonged period of time. As the system is floating on the gastric contents, the drug is slowly released at a specific rate from the system.\(^3,4\) Drugs that are easily absorbed from the gastrointestinal tract and have a short half-life are eliminated quickly from the blood circulation, so there is a need of frequent dosing to maintain therapeutic concentration of drug. To eliminate this limitation, the oral sustained controlled release formulations have been developed in an attempt to release the drug slowly into the gastrointestinal tract and maintain an effective drug concentration in the blood over long period of time.\(^5\)

Ritonavir is a Protease Inhibitor widely prescribed in anti-retroviral regimen. It blocks the HIV protease, thereby reducing the viral load in the infected individual. Ritonavir was initially developed as an independent antiviral agent.\(^6\) Ritonavir mainly suffers with low oral bioavailability due to degradation of Ritonavir by the cytochrome P450-3A4 (CYP3A4) isoenzymes in the distal intestine, efflux of the absorbed drug by counter transporter proteins (mainly P-glycoprotein) present in the distal intestine.\(^7\) Ritonavir is unstable at alkaline pH. It shows pH-dependent solubility and solution stability. pH of Ritonavir is 6.8 and pka is 2.8.\(^8,9\) Biological Half-life is 3-5 hrs.\(^10,11\) It is primarily absorbed from stomach because of these characteristics, it was selected for the development of GRDDS.

MATERIALS AND METHOD

Ritonavir was obtained from micro labs Bangalore as a gift sample. Carbopol 971p, gellan gum and HPMC K 4M were purchased from Sai chemicals, Solapur. All chemicals used in the research work were of analytical grade.

Preformulation Studies:

Solubility study of the drug the solubility of Ritonavir was studied in 0.1N Hcl at 37±0.5 The amount of the drug dissolved was analyzed spectrophotometrically (Systronics UV-Visible double beam spectrophotometer-2201) at 240 nm after suitable dilutions.

Powder flow property: \(^12\)
The flow properties of powders were determined which are the following: bulk density, tapped density, compressibility index (Carr’s index), Hausner’s ratio and angle of repose.

Preparation of Ritonavir floating tablets

All the formulations of Ritonavir floating tablets were prepared by direct compression method. Accurately weighed quantities of polymers were taken in a mortar and mixed geometrically. To this required quantity of Ritonavir was added and mixed slightly with pestle. Accurately weighed quantity of sodium bicarbonate was taken separately in a mortar and powdered with pestle. The powder was passed through sieve No. 40 and mixed with the drug blend which was also passed through sieve No. 40. The whole mixture was collected in a plastic bag and mixed for 5 minutes. To this talc and magnesium stearate was added and mixed for 2 minutes. The mixture equivalent to 300 mg was compressed using Remi Karnawati tablet punching machine.

Post compression studies: \(^{(13,14)}\)

Weight Variation:

20 tablets of each formulation were weighed individually using an electronic balance, average weight was calculated and individual tablet weight was then compared with average value to find the deviation in weight (IP. 2007). Specifications of % weight variation allowed in tablets as per Indian Pharmacopoeia.

Thickness:

The thickness and diameter of the tablets was determined using a Vernier caliper.

Hardness:

For each formulation, the hardness of 5 tablets was determined using Monsanto hardness tester.

Friability:

Friability was measured with Roche Friabilator. A loss of less than 1 % in weight is generally considered acceptable. Percent friability (% F) was calculated as follows,

\[
% F = \left( \frac{\text{Initial Wt.} - \text{Final Wt.}}{\text{Initial Wt.}} \right) \times 100
\]

Drug content uniformity:

Accurately weighed quantity of the powdered tablet equivalent to 100 mg of the drug was transferred to 100ml volumetric flask. To this 50 ml of 0.1N Hcl was added then shaken for 5 minutes and make the final volume with 0.1N Hcl up to 100 ml. Then the solution was sonicated for 15 minutes and filtered and then absorbance was determined at 240 nm using UV spectrophotometer (UV- 2201, Systronics).

Fourier-transform infrared (FTIR) spectroscopy:
Drug-polymer compatibility studies were conducted using FTIR spectrophotometer by KBr pellet technique.

**Differential scanning colorimetry:**

DSC of pure drug and optimized batch was determined.

**Swelling studies:**\(^{(15)}\)

The extent of swelling was measured in terms of % of weight gained by the tablet. One tablet from each formulation was weighed and kept in Petridish containing 50ml of 0.1 N HCL solutions. At the end of specified time intervals tablets were withdrawn from petridish and excess buffer blotted with tissue paper and weighed. The % of weight gained by the tablet was calculated by using the following formula

\[
\text{Swelling index (\%)} = \frac{M_t - M_0}{M_0}
\]

**Buoyancy lag time determination and total Floating time:**

The in-vitro buoyancy was determined by the floating lag time. The tablets were placed in a 250 ml beaker containing 100ml of 0.1 N HCL. The time required for the tablet to rise to the surface for floating was determined as the floating lag time and further duration of all tablets was determined by visual observation.

**In vitro dissolution studies:**\(^{(15)}\)

In vitro drug release studies were conducted for a period of 12 hrs. using USP XXIV type-II (Paddle) dissolution apparatus at 37±0.5°C and at 50 rpm using 900 ml of 0.1N Hcl as dissolution medium. 5 ml of sample was withdrawn at predetermined time intervals from the dissolution medium and replaced with fresh medium to maintain the sink condition. Then, the samples were analyzed for Ritonavir by UV visible spectrophotometer (UV 2201 Systronic) at 240nm.

**RESULTS AND DISCUSSION:**

| Concentration (µg/ml) | Absorbance  |
|----------------------|-------------|
| 0                    | 0           |
| 5                    | 0.134       |
| 10                   | 0.290       |
| 15                   | 0.419       |
| 20                   | 0.565       |
| 25                   | 0.721       |
| 30                   | 0.901       |

Table 2 Ritonavir standard calibration curve
Table 3: Formula for preparing Ritonavir tablet

| Ingredients          | F1   | F2   | F3   | F4   | F5   | F6   |
|----------------------|------|------|------|------|------|------|
| Ritonavir            | 100  | 100  | 100  | 100  | 100  | 100  |
| Carbopol 971p        | 30   | 60   | -    | -    | -    | -    |
| Gellan gum           | -    | -    | 30   | 60   | -    | -    |
| HPMC K4M             | -    | -    | 30   | 60   | 30   | 60   |
| Sodium bicarbonate   | 30   | 30   | 30   | 30   | 30   | 30   |
| Magnesium stearate   | 5    | 5    | 5    | 5    | 5    | 5    |
| Talc                 | 5    | 5    | 5    | 5    | 5    | 5    |
| PVP K30              | 10   | 10   | 10   | 10   | 10   | 10   |
| MCC                  | 110  | 90   | 110  | 90   | 110  | 90   |
| Total                | 300  | 300  | 300  | 300  | 300  | 300  |

The Precompression Parameters:
The Precompression parameters such as bulk density, tapped density, angle of repose, carr’s index and Hausner’s ratio were evaluated. The results of these parameters were found to comply with specification of IP.

Table 4: Precompression parameters:

| Formulation Code | Bulk density | Tapped density | Hausner’s ratio | Carr’s index | Angle of repose |
|------------------|--------------|----------------|-----------------|--------------|-----------------|
| F1               | 0.420        | 0.588          | 1.394           | 28.27        | 37.4±0.15       |
| F2               | 0.428        | 0.600          | 1.401           | 28.66        | 38.9±0.45       |
| F3               | 0.425        | 0.600          | 1.411           | 29.16        | 34.2±0.23       |
| F4               | 0.432        | 0.624          | 1.444           | 30.76        | 32.8±0.35       |
| F5               | 0.425        | 0.603          | 1.4188          | 29.51        | 36.7±0.34       |
| F6               | 0.446        | 0.640          | 1.434           | 30.31        | 38.7±0.43       |

DSC of Ritonavir:
Figure 1: Differential scanning colorimetry for pure Ritonavir

Figure 2: Differential scanning colorimetry for Ritonavir+ HPMC K4M

FTIR:

Figure 3: FTIR of pure Ritonavir
Figure 4: FTIR of carbopol 971p+Ritonavir

Figure 5: FTIR of Gellan gum+Ritonavir
Post compression parameters:

Ritonavir Floating tablet was prepared by direct compression using different polymers in different ratios. In these formulations hardness is in the range of 4.5-5.1 kg/cm². Weight variation in the range of 298-301 mg. Friability is in the range of 0.17-0.22%. Thickness is about 3.2-3.9 mm. The drug content was found to be in the range of 94.21-98%.

Table 5: Post compression parameters for the Ritonavir tablet:

| Formulation | Weight Variation (mg) | Hardness (Kg/cm²) | Thickness (mm) | Friability (%) | Drug Content |
|-------------|-----------------------|-------------------|----------------|----------------|--------------|
| F1          | 300                   | 4.5               | 3.8            | 0.21           | 96.01        |
| F2          | 301                   | 4.7               | 3.9            | 0.23           | 94.21        |
| F3          | 298                   | 4.6               | 3.6            | 0.22           | 95.12        |
| F4          | 302                   | 4.5               | 3.7            | 0.21           | 94.6         |
| F5          | 301                   | 5.2               | 3.4            | 0.18           | 97.36        |
| F6          | 300                   | 5.5               | 3.5            | 0.17           | 98.17        |

In-vitro Drug release:

Ritonavir floating tablet containing the formulations F1-F6, in which formulation F1 and F2 containing carbopol 971p shows drug release of 86.8% and 90.37% upto 10 hrs. Formulation F3 and F4 containing gellan gum shows drug release is about 82.67% and 84.25% upto 10 hrs. Formulations F5 and F6 containing HPMC K 4M show drug release is about 93.3% and 97.7% above 12 Hrs. Formulations F5 and F6 shows the highest drug release with prolonged period of time.

Table 6: Cumulative % Drug Release
Cumulative % Drug Release Versus Time (Min) Of Ritonavir Floating Tablet.

Table 7: Post compression parameters

| Formulation code | Buoyancy lag Time (Sec) | Swelling index (%) | Floating duration (hrs) |
|------------------|-------------------------|--------------------|------------------------|
| F1               | 26                      | 42.47              | 10                     |
| F2               | 33                      | 45.15              | 10                     |
| F3               | 20                      | 62.79              | 10                     |
| F4               | 24                      | 69.20              | 10                     |
| F5               | 12                      | 60.3               | ≥12                    |
| F6               | 14                      | 71.6               | ≥12                    |

Floating characteristic of Ritonavir tablet:

CONCLUSION

From the result of the study, it is concluded that Ritonavir Gastroretentive floating tablets prepared from natural, semi-synthetic and synthetic polymers with different concentration have the ability
to release the drug over prolonged period of time. In comparison to carbopol 971p (F1 and F2) and gellan gum (F3 and F4) HPMC K4M (F5 and F6) shows better drug release. HPMC K4M shows the highest drug release with prolonged period of time. Batch F6 is the optimized batch with highest drug release of 97.7% above 12 hrs.

ACKNOWLEDGEMENT

The authors are thankful to D.S.T.S. Mandal’s College of Pharmacy, Solapur, Maharashtra India for providing raw materials and necessary facility to carry out this research work successfully. The authors are also thankful to Prof. Krishnmurthy A. Kamlapurkar for providing consistent support and timely guidance.

REFERENCES

1. Mohamed HG Dehghan Furquan N Khan, Gastroretentive Drug Delivery Systems: A Patent Perspective. International Journal of Health Research, March 2009; 2(1):23-44.
2. Harish Dureja, Beena Kumari, Parijat Pandey, Formulation and Characterization of Gastroretentive Floating Tablets of Atorvastatin Calcium using Central Composite Design. Journal of Pharmaceutical Research, 2017; 16(3):247-256.
3. Shireesh Kiran, Vishnu.P, Sahitya Lakshmi. Formulation and Evaluation of Floating Tablets of Atazanavir. IOSR Journal Of Pharmacy, 2018; 8(6):33-53.
4. Chanchal, Saurav kumar, satinder Kakar, A Review on floating tablet. Indian Journal Of Pharmaceutical And Biological Research(IJPBR),2018;6(1):22-29.
5. Uroko Robert Ikechukwu, Dingwoke Emeka John Francis, Ambi AA. Development And Evaluation Of Ritonavir Hollow Microballoons For Floating Drug Delivery. Universal Journal of Pharmaceutical Research,2017;2(2):30-34.
6. Pistell PJ, Gupta S, Knight AG, Domingue M, Uranga RM, Ingram DK, et al. Metabolic and neurologic consequences of chronic lopinavir/Ritonavir administration to C57BL/6 mice. Antiviral Res 2010; 88(3):334-42.
7. Shayeda Shaik, Saritha Chukka, Development And Characterization Of Gastroretentive Drug Delivery System For Ritonavir Tablets Using Natural Polymers.asia ournal of parmacetical and clinical resrarch,2017;10(5):318-322.
8. Ritonavir. [internet] [cited 2018 july 24]. Available from:https://www.drugbank.ca/drg/DB00503
9. J.J. Leno Jenita, Madhusudhan N.T, B.Wilson. Formulation And Characterization of Ritonavir Loaded Ethyl Cellulose Microspheres For Oral Delivery. World Journal of Pharmaceutical Research, 2012; 1(2):207-215.

10. Ritonavir. [internet] [cited 2018 july 24]. Available from: http://pubchem.ncbi.nlm.nih.gov/compound/Ritonavil

11. Pistell PJ, Gupta S, Knight AG, Domingue M, Uranga RM, Ingram DK, et al. Metabolic and neurologic consequences of chronic lopinavir/Ritonavir administration to C57BL/6 mice. Antiviral Res 2010;88(3):334-42

12. Harish Dureja, Beena Kumari, Parijat Pandey. Formulation and Characterization of Gastroretentive Floating Tablets of Atorvastatin Calcium using Central Composite Design. Journal of Pharmaceutical Research, 2017:16(3):247.

13. Subramanyam C.V.S, Textbook of physical pharmaceutics, 2nd ed. New Delhi: Vallabh Prakashan: 2001, P.253-261.

14. Aulton M.E, Pharmaceutics: The science of dosage form design, 2nd ed. Churchill Livingstone, London: 2002, P.322-334.

15. Shayeda Shaik, Saritha Chukka. Development and characterization of gastroretentive drug delivery system for Ritonavir tablets using natural polymers. Asian journal of pharmaceutical and clinical research, 2017; 10(5):318-322.